Short-term effects on physical activity level with web-based self-management support in people with COPD: a randomised controlled trial

Introduction

Decreased physical activity (PA) has been shown at an early stage of disease progression in people with chronic obstructive pulmonary disease (COPD)1. Lower number of steps per day independently predict future exacerbations and COPD-related hospitalisations2 and those who are more physically active have, independent of lung function, lower healthcare utilisation, lower risk of hospitalisation3,4 and death5.

Self-management support, including strategies for increased PA level, is a vital component of the management of COPD6. For instance, an increase of 600 steps per day has been found to be associated with a lower risk of hospitalisations7. Self-management interventions are directed towards behavioural change, which is particularly important when aiming to increase PA level8. The interventions are often personalised, structured and multicomponent9, and can, in addition to PA, target symptom management, smoking cessation and dietary intake10. They aim to empower the individual through increased knowledge, skills, and confidence in successfully managing the disease6. Studies have shown that people with COPD who use self-management strategies have improved health-related quality of life (HRQOL), decreased risk for respiratory-related hospital admissions, less depressive symptoms, and improved exercise capacity10. However, access to and knowledge about self-management strategies for people with COPD are limited in primary healthcare11,12.

Electronic health (eHealth), i.e., the use of information and communication technologies in health services, has emerged as a promising strategy to improve the limited access to evidence-based treatment in people with COPD13,14. People with COPD, as well as healthcare professionals (HCPs), have voiced that eHealth interventions can improve healthcare delivery and provide COPD self-management support15. Whether self-management support provided through a web-based platform or a smartphone application in combination with a pedometer could be used to promote PA needs further investigation as previous randomised controlled trials (RCTs) have shown both positive16,17,18,19 as well as no effects20 on PA levels. We have previously, in co-creation with people with COPD, their relatives, and HCPs, developed the COPD Web, to support people with COPD in their self-management strategies and to facilitate the provision of self-management support from the HCPs21. The COPD Web has been described as a suitable eHealth tool to provide self-management support22, and a pilot study showed that access to the COPD Web for 3 months increased self-reported PA levels, improved COPD-specific knowledge, and altered self-management strategies23. The primary aim of the present study was to evaluate the short-term effects of the use of the COPD Web on objectively measured PA level compared to usual care in people with COPD in primary healthcare. A secondary aim was to evaluate the short-term effects on self-reported PA level, dyspnoea, COPD-related symptoms, and HRQOL compared to usual care. We hypothesised that people who used the COPD Web as a strategy to change PA behaviour would increase their PA levels to a larger extent than people given usual care.

Materials and methods

Study design and participants

We conducted a pragmatic, parallel-group RCT in a primary healthcare context with a 3- and 12-month follow-up, of which the present study will report on the 3-month results. The trial was registered at ClinicalTrials.gov (NCT03746873) and the trial protocol was published24. Ethical approval was received from the Regional Ethical Review Board in Umeå, Sweden (Dnr: 2018-274-31, 2019-05572). All participants gave written informed consent to participate in the study. The study was reported following the CONSORT statement for RCTs and the extension for pragmatic trials25.

Participants were recruited through HCPs at 25 primary healthcare units situated in urban and rural areas in six different County Councils in Sweden and via advertisements in newspapers and Facebook during the period of November 2018 to March 2021. The last follow-up assessments were finalised in June 2022. During the trial, the Covid-19 pandemic caused restrictions from March 2020 to February 2022. Participants with stable COPD26 who made a regular visit to any of the involved primary healthcare units due to their COPD or those who contacted the research group due to advertisement were eligible for inclusion if they (1) could read and understand Swedish, (2) had a smartphone, tablet or computer with access to internet, (3) did not have dementia or other psychiatric condition that may prevent understanding of the intervention, (4) did not have severe comorbidity that could be considered as the contributing factor for limitation in PA, and (5) did not already use the COPD Web24. Results from participants’ latest pulmonary function test were used to verify the COPD diagnosis. After verbal agreement, an informed consent form, questionnaires, and an accelerometer for baseline assessment were sent to the participants.

Randomisation and blinding

Participants were randomly allocated in a 1:1 allocation ratio to usual care with or without access to the COPD Web, after completion of the baseline assessment. A colleague, otherwise not involved in the study, performed the allocation using a computer-generated randomisation list and the results were stored in sealed envelopes. The randomisation was revealed for the researcher when the sealed envelope next in order was opened and the letter containing the allocation was sent to the participant. Blinding of participants and outcome assessors was not applicable since data was either self-reported or objectively measured by an accelerometer.

Intervention

The intervention is previously described in detail24. In brief, the COPD Web aims to improve and support self-management of the disease with a special focus on PA. The COPD Web includes informative texts, pictures, films, and interactive components (i.e., step registration with automatised feedback), which aligns with the guidelines for COPD care developed by the National Board of Health and Welfare in Sweden27. An overview of the content is shown in Fig. 1. The intervention was designed to minimise the efforts required from HCPs and researchers. The participants were introduced to the COPD Web by a letter with written instructions on how to create an account. In addition, an instruction movie with standardised information was available on the website. They were also provided with a pedometer, a leaflet targeting the importance of PA, and information about when they would be contacted for the follow-up assessment. The participants in the intervention group were also contacted once by one of the researchers during the first week to reduce possible user problems. Thereafter, the participants received predetermined prompts via email and SMS, including targeted information, referral links to the COPD Web, and encouragement to register counted steps. The prompts were delivered once a week for the following 3 months. No other contacts between the participants and the researchers or the HCPS were included in the intervention. During the RCT, the COPD Web was secured with login and only minor adjustments, e.g., research news or new links, were added.

Fig. 1: A website map of the COPD Web showing the section ‘I have COPD’24.
figure 1

Reprinted under the terms of the Creative Commons CC BY 4.0 license.

Full size image

Control group

All participants received usual care24. Similar to the intervention group, the control group received a pedometer with instructions and a leaflet targeting the importance of PA, but no other contacts besides the follow-up assessment. During the study, the participants were free to participate in other interventions in the community or at their primary healthcare unit.

Outcomes

Full details on outcomes and assessment procedures are available in the study protocol24. Concisely, the primary outcome was the difference in PA level, measured as steps per day, between intervention and control groups at 3 months. The PA level was objectively measured for seven consecutive days using an accelerometer (DynaPort, McRoberts BV, the Netherlands). According to recommendations, only measurements with ≥4 valid weekdays were included, i.e., weekends were excluded, as well as weekdays with <8 h of daytime accelerometer wearing time28. Secondary outcomes were self-reported PA level measured by indicator questions from the National Board of Health and Welfare in Sweden29, dyspnoea measured by modified Medical Research Council dyspnoea scale (mMRC)30, HRQOL measured by the self-administered Chronic Respiratory Questionnaire (CRQ-SA)31, COPD-related symptoms measured by the COPD Assessment Test (CAT)32, and self-reported healthcare contacts.

Sample size

The trial was designed to detect a mean difference of 1131 steps, which has previously been determined as a minimal important difference in people with COPD7. Demeyer et al.7 reported a standard deviation in PA level of 2193 steps after 3 months of Pulmonary Rehabilitation (PR) in a sample of people with COPD. Assuming the same standard deviation in the present trial and a dropout rate of 20% in both groups, 144 participants would be required to reach a power of 80% for detecting a group difference of 1131 steps when using a two-tailed independent sample t-test.

Statistical methods

Descriptive statistics was calculated by group. Further, a dropout analysis comparing participant lost to follow-up with the full analysis set was performed.

Group comparisons of the primary outcome were made using ANCOVA, with PA level at 3 months as dependent variable and group, baseline PA level, age and sex as independent variables. Age was entered into the model using restricted cubic splines with three knots, placed at the 10th, 50th and 90th percentile of the age distribution to account for non-linear relationship. In accordance with CONSORT, unadjusted models were fitted as sensitivity analysis. Assumptions of normally distributed and homoscedastic residuals were examined from graphs.

The secondary outcomes, self-reported PA and CAT were analysed using the same ANCOVA model as for the primary outcome. The mMRC and CRQ-SA were analysed using ordinal proportional odds models with 3-month measurements as dependent variable and group, baseline PA, age and sex as independent variables. Assumptions of proportional odds were examined by investigating the stability of the odds ratio between group, as estimated from binary logistic regression when dichotomising the scales at different locations.

The primary analysis approach was intention-to-treat (ITT). Analyses were performed on data with multiple imputation by chained equations (MICE) using partial mean matching to address potential bias from missing values due to dropout. The results were obtained by fitting the statistical model on each of the 30 imputed data sets and thereafter pooling the results using Rubin’s rule. The imputations were performed separately within the intervention arms. Additional details on the imputation model can be found in the online supplementary material (Supplementary Methods). Further, a planned complete case analysis was performed, i.e., including participants with full outcome measurements independent on adherence to the intervention. In accordance with the study protocol, a complementary per-protocol analysis was also planned with a predetermined definition of per-protocol population24. However, as only two participants from the ITT population did not adhere to per-protocol definition, resulting in close to identical results as the ITT analysis, the per-protocol analysis was deemed redundant.

A significance level of 5% was used in all statistical tests. The descriptive analyses were performed using SPSS (V.28.0; IBM Corp.), while the statistical modelling was performed using R v 4.3.0. The proportional odds models were fitted using the function orm from the R package rms33. The multiple imputations were made using the mice package34.

Results

Of the 200 eligible participants, 146 were randomised to either the intervention (n = 73) or control (n = 73) group and included in the analysis (Fig. 2). Baseline characteristics of participants are shown in Table 1. Participants who had missing data on PA at 3 months had a significantly higher CAT-score (p = 0.04) and took fewer steps per day (p < 0.01) at baseline than those who had full outcome measurements (see results from the dropout analysis in Supplementary Table 1).

Fig. 2
figure 2

Flowchart of the participants in the RCT.

Full size image
Table 1 Participant characteristics.
Full size table

Primary outcome

No significant difference in change in daily steps between the groups was seen at 3 months in the ITT analysis, 1295 steps (95% CI: [−365, 2955], p = 0.12). The complete case analysis (n = 98) showed, however, a significant and clinically relevant difference of 1491 steps per day (95% CI: [374, 2607], p = 0.01) in favour of the intervention group. Figure 3 shows the distribution of PA at baseline and 3 months for the groups in the ITT (Fig. 3a) and the complete case analysis (Fig. 3b), respectively.

Fig. 3: Mean daily steps and distribution for groups at baseline and at 3-month follow-up.
figure 3

a Intention-to-treat analysis. b Complete case analysis.

Full size image

Secondary outcomes

Self-assessed PA level was significantly higher in the intervention group compared to control group in both the ITT 1.8 (95% CI: [0.3, 3.4], p = 0.02) and the complete case 1.8 (95% CI: [0.5, 3.0], p = 0.01) analysis. No other between-group differences were found in the secondary outcomes. Results of the ITT analyses are presented in Table 2 while the complete case analyses are provided as online supplementary material (Supplementary Table 2).

Table 2 Secondary outcomes—intention-to-treat analysis.
Full size table

Nine of the participants reported COPD-related healthcare contacts at 3 months, five in the intervention and four in the control group, of whom two of the controls had been hospitalised. Furthermore, nine participants in the intervention group and eight in the control group had participated in COPD-related education or in a PR programme after being enrolled to the study.

Discussion

The ITT analysis did not confirm our hypothesis that use of web-based self-management support along with a pedometer would increase objectively measured PA level at 3 months compared to usual care combined with a pedometer in people with COPD. However, the web-based self-management support did increase self-reported PA level, and among those with complete step data at 3 months, a significant and clinically relevant larger increase in objectively measured PA level was found in favour of the intervention group. No between-group differences were seen in COPD-related symptoms or HRQOL which, at least partly, could be explained by low baseline symptom burden and high baseline HRQOL, thus reducing the room for improvement.

The positive effect on self-reported PA level among those who had access to the COPD Web was comparable to that found in the pilot trial23. The fact that self-reported and not objectively measured PA increased may reflect that PA is a complex outcome. Self-reported outcome measures may capture PA in a broader sense with focus on the PA experience rather than the actual performance, i.e., number of steps28. Some discrepancy between subjective and objective PA measurement could also be due to the risk of recall bias when PA is self-reported35. Despite the lack of a statistically significant increase in objective PA, the observed difference surpassed the MCID for PA in COPD, which ranges from 600 to 1100 steps per day7. Additionally, the increase in self-reported PA levels supports these findings and is noteworthy in its own right, as higher self-reported PA has been linked to key clinical outcomes, including reduced mortality in older adults36. Furthermore, among individuals with COPD, increased self-reported PA has been associated with improved clinical outcomes such as physical capacity, HRQoL and reduced dyspnoea37. Nevertheless, the result indicates that the intervention had a positive impact on the participants’ everyday activities. Regarding the effect on objectively measured PA, our results from the complete case analyses suggest that the COPD Web intervention may be effective in increasing PA in some individuals, while others may need more support or other type of interventions. This is in line with Troosters et al. 38, who suggest that interventions in people with COPD with low exercise tolerance or severe symptom burden should primarily focus on increasing exercise tolerance before enhancing PA. Notably, those who were lost at follow-up, thus included in the ITT but not the complete case analysis, had lower baseline PA level, compared to those who completed the study procedures. This indicates that less active individuals may need additional support, which is in accordance with a previous systematic review and meta-analysis demonstrating that individuals with higher compared to lower baseline PA level showed greater improvements in steps per day after an intervention39. The need for additional support to increase PA in subgroups of people with COPD is also supported by the information obtained from our qualitative interviews in a subset of the participants in the RCT with a wide variation in characteristics and of using the tool40. Within this subset, we observed that for those who were ready and capable to use the COPD Web, it seemed to provide practical, emotional, and psychological help to incorporate measures needed for a behaviour change resulting in increased PA levels. The qualitative interviews also revealed that the COPD Web seemed to strengthen or weaken the perception of control by either providing support or being too demanding on the user, supporting the notion that a web-based self-management intervention might be a suitable and effective alternative to improve PA in some, but not all people with COPD40. These data also suggest that a potentially explanatory mechanism for the results seen among those who completed the full 3-month intervention period is that the COPD Web was successful in empowering the participants to boost their level of agency and their ability to improve PA levels. Similarly, Slevin et al.41 reported that those who had the capacity to engage in an eHealth tool perceived that it supported their self-management ability, increased their self-efficacy to manage the disease, reduced their anxiety, and facilitated personalised care

Finding ways to promote a beneficial PA behaviour in people with COPD is indeed a challenge and the most optimal intervention is yet to be determined8. The present study provides further support for the notion that low PA levels can occur across a broad spectrum of people with COPD, not only among those with a high symptom and disease burden. Previous interventions that enhanced short-term PA have, for instance, combined a pedometer with five individual counselling sessions42 or with a tele-coaching intervention including a motivational interview with a HCP19. Other studies had an online social support forum included in the eHealth tool16,17. The present study was designed to have minimal involvement from the HCPs as well as the researchers, even though it was a standalone intervention and not delivered following a PR programme. To facilitate PA, interactive parts, e.g., weekly step goal, step registration, and automated feedback, were included in the COPD Web, components that have shown to be beneficial for behavioural change9. Although our findings suggest that this was only sufficient to increase PA levels among those with complete outcome data, that is, those who were shown to have more preserved baseline PA. The intervention might have been more successful for those with a lower baseline PA if individualised support from the HCPs and/or the researchers had been included as part of the intervention. This could have boosted the participants’ self-efficacy in improving PA and guided them in finding an appropriate level of PA that could be incorporated into their daily lives, as suggested by Kosteli et al.43. Evidently, eHealth interventions may not be the best treatment option for all people with COPD but should, according to Kermelly et al.44, be incorporated into regular care as an adjunct or enhancement to existing self-management interventions. In clinical practice, it seems important for HCPs to have a patient-centric approach when considering the suitability of a digital self-management support alternative for their patients.

Methodological considerations

Strengths of the study are that the COPD Web was developed in co-creation with end-users and had a pragmatic study design with participation at a distance with few restrictions on what other interventions the participants took part in, which reflects reality. Participation in other interventions, such as COPD-related education or in a PR programme, might be a confounding factor, but few participants had received such interventions, and the distribution was comparable between the groups at the 3-month follow-up. The pragmatic design also allowed the study to proceed despite the restrictions of the COVID-19 pandemic that designated people with COPD at high risk for severe symptoms45, although it is difficult to determine to what extent the pandemic affected the study results. Other strengths are that PA level was measured in accordance with the recommendations from the international task force on PA28 and that we used a robust imputation procedure to address the potential bias that can occur when values are missing due to dropout46. The HCP’s input, if any, was kept to a minimum to preserve the participant’s self-management and no participant was after the pandemic asked to seek their PHCs for updated spirometry or health data in case something was missing. On the other hand, this limits the possibility of determining the participant’s capacity and compliance with the intervention.

There are some limitations to address. The extent to which the COPD Web was used is not known since the new interpretation of GDPR during the study made user analyses prohibited. The dropout rate was greater than expected, which may partly be due to the pandemic. The main reasons for refusing participation in the follow-up assessment were e.g., that they had stopped their normal social activities or had stopped exercising, which indicated that they saw the follow-up as pointless. Another reason was that people with the opportunity left the cities and spent more time in their summer houses where they had limited mail and internet connection. It is also possible that the study design, which involved few personal contacts with the HCPs and the researchers, and the fact that the intervention was not personally tailored could have contributed to participants withdrawing from the study. It is worth noticing, though, that 67% of all participants had complete outcome data, despite the potential negative impact of the COVID-19 pandemic, and among those, a statistically significant but also clinically relevant mean improvement of more than 1400 steps per day was observed. Another limitation is that the health literacy and patient activation among the participants are not known. This means that we do not know if they had the skills and confidence required for a self-management intervention, as well as if they were motivated and had the capacity to take action47. Moreover, despite that the study evaluated an eHealth intervention, we did not consider digital health literacy when including participants in the study, which has been reported to be a common patient barrier to the adoption of eHealth interventions15. Lastly, we have not yet evaluated the 12-month effects of the intervention, which will show if the intervention had a long-term effect on PA level. As part of the previously mentioned pilot trial23, a qualitative study of participants who had access to the COPD Web for 12 months found that time was needed to be able to incorporate knowledge from the tool into everyday life, indicating that changes in health behaviour such as increasing PA level may take up to a year22.

In summary, the ITT analysis found that a web-based self-management support demanding minimal effort from HCPs, was not sufficient to increase PA level in people with COPD. Still, the complete case analysis found a significant and clinically relevant increase in level of PA, indicating a benefit of the web-based support in participants with complete step data. Participants in both control and intervention groups lost to follow-up had a lower PA level at baseline, which likely is one of the factors that contributed to the observed differences in the ITT and complete case analysis, and which highlights the need for additional support and interventions in those with lower baseline PA. It is important to identify people who may benefit from using web-based support for increasing their PA levels in order to use HCP resources in primary healthcare as effectively as possible.

Related Articles

A 7-point evidence-based care discharge protocol for patients hospitalized for exacerbation of COPD: consensus strategy and expert recommendation

Acute exacerbations of COPD (ECOPD) are an important event in the life of a COPD patient as it causes significant deterioration of physical, mental, and social health, hastens disease progression, increases the risk of dying and causes a huge economic loss. Preventing ECOPD is therefore one of the most important goals in the management of COPD. Before the patient is discharged after hospitalization for ECOPD, it is crucial to offer an evidence-based care bundle protocol that will help minimize the future risk of readmissions and death. To develop the content of this quality care bundle, an Expert Working Group was formed, which performed a systematic review of literature, brainstormed, and debated on key clinical issues before arriving at a consensus strategy that could help physicians achieve this goal. A 7-point consensus strategy was prepared, which included: (1) enhancing awareness and seriousness of ECOPD, (2) identifying patients at risk for future exacerbations, (3) optimizing pharmacologic treatment of COPD, (4) identifying and treating comorbidities, (5) preventing bacterial and viral infections, (6) pulmonary rehabilitation, and (7) palliative care. Physicians may find this 7-point care bundle useful to minimize the risk of future exacerbations and reduce morbidity and mortality.

Deep learning for detecting and early predicting chronic obstructive pulmonary disease from spirogram time series

Chronic Obstructive Pulmonary Disease (COPD) is a chronic lung condition characterized by airflow obstruction. Current diagnostic methods primarily rely on identifying prominent features in spirometry (Volume-Flow time series) to detect COPD, but they are not adept at predicting future COPD risk based on subtle data patterns. In this study, we introduce a novel deep learning-based approach, DeepSpiro, aimed at the early prediction of future COPD risk. DeepSpiro consists of four key components: SpiroSmoother for stabilizing the Volume-Flow curve, SpiroEncoder for capturing volume variability-pattern through key patches of varying lengths, SpiroExplainer for integrating heterogeneous data and explaining predictions through volume attention, and SpiroPredictor for predicting the disease risk of undiagnosed high-risk patients based on key patch concavity, with prediction horizons of 1–5 years, or even longer. Evaluated on the UK Biobank dataset, DeepSpiro achieved an AUC of 0.8328 for COPD detection and demonstrated strong predictive performance for future COPD risk (p-value < 0.001). In summary, DeepSpiro can effectively predict the long-term progression of COPD disease.

Smoking status, symptom significance and healthcare seeking with lung cancer symptoms in the Danish general population

This study analyses the associations between smoking status and perceived symptom significance (concern and influence on daily activity) among individuals with possible lung cancer symptoms and investigate the influence of symptom significance on healthcare seeking among individuals with different smoking status. A nationwide survey with 21,920 randomly selected individuals aged ≥40 years included questions about lung cancer symptoms, symptom concern and influence on daily activities, GP contact, and smoking status. Descriptive statistics and multivariable regression models were applied. Overall, individuals who currently smoked were more likely to perceive their lung cancer symptoms as significant, and individuals who reported high symptom significance were more likely to seek healthcare with both specific and non-specific symptoms. The significance of symptoms appeared to have less pronounced effect on prompting healthcare seeking among individuals with a history of current smoking. This implies that they may benefit from support and encouragement to seek care.

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects

The muscular system plays a critical role in the human body by governing skeletal movement, cardiovascular function, and the activities of digestive organs. Additionally, muscle tissues serve an endocrine function by secreting myogenic cytokines, thereby regulating metabolism throughout the entire body. Maintaining muscle function requires iron homeostasis. Recent studies suggest that disruptions in iron metabolism and ferroptosis, a form of iron-dependent cell death, are essential contributors to the progression of a wide range of muscle diseases and disorders, including sarcopenia, cardiomyopathy, and amyotrophic lateral sclerosis. Thus, a comprehensive overview of the mechanisms regulating iron metabolism and ferroptosis in these conditions is crucial for identifying potential therapeutic targets and developing new strategies for disease treatment and/or prevention. This review aims to summarize recent advances in understanding the molecular mechanisms underlying ferroptosis in the context of muscle injury, as well as associated muscle diseases and disorders. Moreover, we discuss potential targets within the ferroptosis pathway and possible strategies for managing muscle disorders. Finally, we shed new light on current limitations and future prospects for therapeutic interventions targeting ferroptosis.

Type 2 immunity in allergic diseases

Significant advancements have been made in understanding the cellular and molecular mechanisms of type 2 immunity in allergic diseases such as asthma, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis (EoE), food and drug allergies, and atopic dermatitis (AD). Type 2 immunity has evolved to protect against parasitic diseases and toxins, plays a role in the expulsion of parasites and larvae from inner tissues to the lumen and outside the body, maintains microbe-rich skin and mucosal epithelial barriers and counterbalances the type 1 immune response and its destructive effects. During the development of a type 2 immune response, an innate immune response initiates starting from epithelial cells and innate lymphoid cells (ILCs), including dendritic cells and macrophages, and translates to adaptive T and B-cell immunity, particularly IgE antibody production. Eosinophils, mast cells and basophils have effects on effector functions. Cytokines from ILC2s and CD4+ helper type 2 (Th2) cells, CD8 + T cells, and NK-T cells, along with myeloid cells, including IL-4, IL-5, IL-9, and IL-13, initiate and sustain allergic inflammation via T cell cells, eosinophils, and ILC2s; promote IgE class switching; and open the epithelial barrier. Epithelial cell activation, alarmin release and barrier dysfunction are key in the development of not only allergic diseases but also many other systemic diseases. Recent biologics targeting the pathways and effector functions of IL4/IL13, IL-5, and IgE have shown promising results for almost all ages, although some patients with severe allergic diseases do not respond to these therapies, highlighting the unmet need for a more detailed and personalized approach.

Responses

Your email address will not be published. Required fields are marked *